Literature DB >> 1334280

The current status of toxicity protectants in cancer therapy.

L M Schuchter1, W E Luginbuhl, N J Meropol.   

Abstract

Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article reviews a variety of agents that have been evaluated as possible protectants, including WR-2721 and the colony-stimulating factors. It is hoped that the understanding of how to optimally use chemoprotective agents will lead to more tolerable treatments for patients, and possibly allow for dose-escalation, which may contribute to improvement in patient survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334280

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  5 in total

1.  Topical application of honey in the management of radiation mucositis: a preliminary study.

Authors:  Biswa Mohan Biswal; Ahmad Zakaria; Nik Min Ahmad
Journal:  Support Care Cancer       Date:  2003-02-19       Impact factor: 3.603

Review 2.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 3.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

4.  Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

Authors:  D C Betticher; H Anderson; M Ranson; K Meely; W Oster; N Thatcher
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

5.  Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines.

Authors:  N Suzuki; S Sekiya; I Sugano; T Kojima; H Yamamori; Y Takakubo
Journal:  Jpn J Cancer Res       Date:  1995-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.